Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy

Last updated: January 20, 2025
Sponsor: Wake Forest University Health Sciences
Overall Status: Active - Recruiting

Phase

2

Condition

Mucositis

Canker Sores

Treatment

Virgin Coconut Oil

Clinical Study ID

NCT05441813
LCI-PED-BMT-MUC-001
00061628
  • Ages 7-26
  • All Genders

Study Summary

The purpose of this study is to learn if virgin coconut oil (VCO) mouth rinse can help prevent oral mucositis. The Study Investigator will compare standard of care mucositis prevention rinses with the VCO mouth rinse added to the standard of care mucositis prevention rinses. The severity of oral mucositis between the 2 groups will be evaluated. Some of the standard of care rinses that can be used to prevent mucositis are normal saline, Benadryl (diphenhydramine), Mylanta, lidocaine, or other combinations.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Subject must meet all the following applicable inclusion criteria to participate in this study:

  1. Written informed consent, HIPAA authorization for release of personal healthinformation, and assent, when applicable from the subject, parent, or legalguardian.

  2. Age greater than or equal to 7 years to 26 years at the time of consent

  3. Patients planning to undergo myeloablative conditioning regimens in preparation forHSCT

  4. ECOG Performance Status of less than or equal to 2 or Lansky/Karnofsky PerformanceStatus of greater than or equal to 50 within 7 days prior to date of enrollment.

  5. No evidence of mouth lesions at time of enrollment

  6. Ability of the subject and parent/caregiver to understand and comply with studyprocedures for the entire length of the study

  7. Able and willing to swish/spit the oral formulation

Exclusion

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

  1. Allergy to tree nuts

  2. Planned discharge home prior to engraftment

  3. Using coconut oil mouth rinses within 30 days prior to enrollment

  4. Using additional mouthcare regimens, other than those allowed in the institutionalSOP, prior to admission with a plan to continue use during admission

  5. Patient has undergone HSCT within the last 90 days prior to admission

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Virgin Coconut Oil
Phase: 2
Study Start date:
February 15, 2023
Estimated Completion Date:
August 31, 2025

Study Description

This is a randomized, open-label study. The target population is patients ≥ 7 years to 26 years at time of consent who are planning to undergo myeloablative conditioning regimens in preparation HSCT. The study will be conducted at Levine Children's Hospital, Levine Children's Cancer and Blood Disorders Clinic and Atrium Health. Subjects will be screened and consented within 28 days prior to admission. The planned treatment period for Arm A (standard of care with the addition of VCO mouth rinses) or Arm B (standard of care) will begin at the start of subject's admission for conditioning, followed by transplant event with day of transplant defined as Day 0 and continue through Day +45 following transplant or hospital discharge, whichever comes first. A Safety Follow Up Visit will occur no sooner than 30 days from last study drug treatment

Connect with a study center

  • Atrium Health Levine Children's Hospital

    Charlotte, North Carolina 28203
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.